AcelRx Pharma Revenue, Profits - ACRX Annual Income Statement

Add to My Stocks
$3.45 $0.05 (1.47%) ACRX stock closing price Sep 17, 2018 (Closing)

Fundamental analysis of ACRX stock involves analyzing its financial statements, apart from checking the AcelRx Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $7.99M for 2017 impacts the ACRX stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2017 is $7.99M and has decreased from $17.35M year on year as is evident when you compare the latest figures in the latest AcelRx Pharma profit and loss statement with those of the prior corresponding period. Also see AcelRx Pharma assets and AcelRx Pharma free cash flow for a complete valuation of ACRX stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
AcelRx Pharma Revenues or Net Sales
7.99M17.35M19.26M5.21M29.5M2.39M1.07M---
Cost Of Goods Sold (COGS)10.65M12.31M1.77M-------
AcelRx Pharma Gross Profit
-2.66M5.04M17.49M5.21M29.5M2.39M1.07M---
Research & Development Expense19.4M21.4M22.48M24.52M26.29M24.9M13.62M8.19M15.5M18.32M
Selling General & Admin Expense16.6M15.59M14.95M18.34M9.87M7.19M6.8M3.99M3.52M2.36M
Income Before Depreciation Depletion Amortization-38.68M-31.95M-19.95M-37.64M-6.66M-29.71M-19.35M-12.18M-19.03M-20.69M
Depreciation Depletion Amortization----------
Non Operating Income--1.72M6.93M-15.24M-1.36M1.56M-0.76M--
Interest Expense14.03M12.15M5.4M2.63M1.51M2.28M2.3M1.39M1.24M-
AcelRx Pharma Pretax Income
-52.2M-43.19M-23.63M-33.35M-23.42M-33.36M-20.1M-14.34M-20.11M-20.66M
Provision for Income Taxes-0.7M-0.03M--------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-51.5M-43.15M-24.39M-33.35M-23.42M-33.36M-20.1M-14.34M-20.11M-20.66M
Extraordinary Items & Discontinued Operations----------
AcelRx Pharma Profit/ Loss (Net Income)
-51.5M-43.15M-24.39M-33.35M-23.42M-33.36M-20.1M-14.34M-20.11M-20.66M
Average Shares used to compute Diluted EPS46.88M45.31M44.47M44.32M39.75M22.13M17.35M---
Average Shares used to compute Basic EPS46.88M45.31M44.3M43.43M39.75M22.13M17.35M---
Income Before Nonrecurring Items-51.51M-43.16M-24.4M-34.98M-35.5M-33.36M-20.1M-14.34M--
Income from Nonrecurring Items---1.63M12.07M-----
AcelRx Pharma Earnings Per Share Basic Net
-1.10-0.95-0.55-0.77-0.59-1.51-1.16-21.84--
AcelRx Pharma Earnings Per Share Diluted Net
-1.10-0.95-0.60-0.91-0.59-1.51-1.16-21.84--
EPS Diluted Before Nonrecurring Items-1.10-0.95-0.60-0.95-0.89-1.51-1.16-21.84--
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on AcelRx Pharma stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $7.99M for this year of 2017. Our AcelRx Pharma revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like AcelRx Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The ACRX financials along with AcelRx Pharma historical stock prices provide a lot of details about the firm.

AcelRx Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
52.76
Dividend Yield
0%